UTMD UTAH MEDICAL PRODUCTS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 706698 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.6%
TTM net income YoY-8.4%
TTM EPS YoY-5.6%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR-14.3%
Margins
Gross margin57.7%
Operating margin29.9%
Net margin30.5%
FCF margin31.1%
EBITDA margin32.4%
Returns
ROE8.8%
ROA8.5%
ROIC (approx.)23.7%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets4.1%
Debt / equity0.00x
Current ratio21.23x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.08x
Accruals ratio-0.7%
Payout ratio37.0%
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $38.52M | $40.90M |
| Cost of revenue | $16.52M | $16.76M |
| Gross profit | $22.00M | $24.14M |
| R&D expense | $668,000 | $813,000 |
| SG&A expense | $7.88M | $7.83M |
| Operating income | $11.40M | $13.59M |
| Pretax income | $14.11M | $16.80M |
| Income tax | $2.82M | $2.93M |
| Net income | $11.29M | $13.87M |
| EBITDA | $12.23M | $14.32M |
| EPS (basic) | 3.48 | 3.96 |
| EPS (diluted) | 3.48 | 3.96 |
| Weighted avg. shares (diluted) | 3.24M | 3.50M |
| Balance sheet | ||
| Cash & equivalents | $85.76M | $82.98M |
| Receivables | $3.52M | $4.09M |
| Inventory | $7.93M | $8.81M |
| Current assets | $97.74M | $96.33M |
| PP&E, net | $9.91M | $9.76M |
| Goodwill | $14.05M | $13.58M |
| Intangibles | $840,000 | $2.87M |
| Total assets | $122.54M | $122.54M |
| Current liabilities | $2.60M | $3.76M |
| Long-term debt | $225,000 | $282,000 |
| Total debt | $225,000 | $282,000 |
| Total liabilities | $3.27M | $5.11M |
| Shareholders' equity | $119.27M | $117.43M |
| Net debt | -$85.53M | -$82.69M |
| Shares outstanding | 3.19M | 3.33M |
| Cash flow statement | ||
| Operating cash flow | $14.69M | $14.83M |
| Capital expenditure | $371,000 | $230,000 |
| Free cash flow | $14.32M | $14.60M |
| Investing cash flow | -$371,000 | -$208,000 |
| Financing cash flow | -$12.34M | -$23.84M |
| Depreciation & amortization | $826,000 | $730,000 |
| Stock-based compensation | $373,000 | $256,000 |
| Dividends paid | $3.98M | $4.26M |
| Share buybacks | $8.36M | $19.97M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.